Keyphrases
Opioid Abuse
100%
Monocytes
100%
Buprenorphine
100%
NeuroAIDS
100%
HIV-associated Neurocognitive Disorders
60%
Chemokine (C-C motif) Ligand 2 (CCL2)
40%
Methadone
30%
Opioid Receptors
30%
CD16+ Monocytes
20%
EcoHIV
20%
Cognitive Impairment
20%
Brain Diseases
20%
CD14+CD16+
20%
HIV Patients
20%
Blood-brain Barrier
20%
Opiates
20%
Circulating Leukocytes
10%
Injection Drug Use
10%
Opiate Addiction
10%
Therapeutic Goals
10%
Opioids
10%
Infected Mice
10%
HIV-associated Dementia
10%
Safety Profile
10%
MOR Agonists
10%
HIV Neuropathogenesis
10%
Brain Microvascular Endothelium
10%
Chemokines
10%
CD14+ Monocytes
10%
Opioid Users
10%
Chronic Neuroinflammation
10%
Immunodeficient
10%
Transmigration
10%
Monocyte Migration
10%
Monocyte Transmigration
10%
Inflammation
10%
Mild Forms
10%
Opiate Users
10%
Opiate Abuse
10%
Chemotaxis
10%
Risky Behavior
10%
Adhesion
10%
HIV DNA
10%
Neuroinflammation
10%
Partial Agonist
10%
Abusers
10%
HIV+
10%
Non-drug
10%
HIV Infection
10%
Antiretroviral Therapy
10%
Infected Cells
10%
Cognitive Function
10%
Chemokine CCL2
10%
Uninfected Cells
10%
Mouse Model
10%
Neuroscience
Buprenorphine
100%
Human Immunodeficiency Virus
100%
HIV Associated Dementia
63%
CD14
45%
CD16
36%
CCL2
36%
Opiate
27%
Methadone
27%
Receptor
27%
Agonist
18%
Blood Brain Barrier
18%
Cognitive Disorders
18%
Brain Disease
18%
Opioid Dependence
9%
Opiate Abuse
9%
In Vitro
9%
Monocyte Chemotactic Protein 1
9%
Cognitive Function
9%
Leukocyte
9%
Chemokine
9%
Chemotaxis
9%
Risk Behavior
9%
Pharmacology, Toxicology and Pharmaceutical Science
Buprenorphine
100%
HIV
100%
HIV Associated Dementia
70%
Opiate
40%
Methadone
30%
Opiate Receptor
30%
Cognitive Defect
20%
Brain Disease
20%
Nervous System Inflammation
20%
Blood-Brain Barrier
20%
Opiate Addiction
10%
Preclinical Study
10%
Mouse Model
10%
Partial Agonist
10%
Chemokine
10%
Clinical Study
10%
Monocyte Chemotactic Protein 1
10%
Human Immunodeficiency Virus Infection
10%
Inflammation
10%
Diseases
10%